A Kaposi's sarcoma complete clinical response after sorafenib administration

Annals of Oncology

Volumn 19, Issue 9, 2008, Pages 1658-1659

  Ardavanis, A ^a   Doufexis, D ^a   Kountourakis, P ^a   Rigatos, G ^a  

^a SAINT SAVVAS HOSPITAL   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

SORAFENIB; SUNITINIB;

ADULT; ARTICLE; BRAIN METASTASIS; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER PREVENTION; CANCER RADIOTHERAPY; CANCER REGRESSION; CARDIOVASCULAR RISK; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; CORONARY ARTERY DISEASE; DRUG EFFICACY; DRUG ERUPTION; HUMAN; KAPOSI SARCOMA; KIDNEY CARCINOMA; MALE; PRIORITY JOURNAL; STEREOTACTIC RADIOSURGERY; TREATMENT RESPONSE; TUMOR BIOPSY;

EID: 50849126469     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdn528     Document Type: Article

References (4)

1. Boshoff C, Weiss R. AIDS-related malignancies. Nat Rev Cancer 2002; 2(5): 373-382.
2. Cornali E, Zietz G, Benelli R et al. Vascular endothelial growth factor regulates angiogenesis and vascular permeability in Kaposi's sarcoma. Am J Pathol 1996; 149(6): 1851-1869.
3. Samaniego F, Markham PD, Gendelman R et al. Vascular endothelial growth factor and basic fibroblast growth factor present in Kaposi's sarcoma (KS) are induced by inflammatory cytokines and synergize to promote vascular permeability and KS lesion development. Am J Pathol 1998; 152(6); 1433-1443.
4. Flaherty KT. Sorafenib in renal cell carcinoma. Clin Cancer Res 2007; 13: 747s-752s.